Benzinga | May 12, 2021 04:51PM EDT

Iovance Biotherapeutics Highlights Publication Of Clinical Data For Cohort 2 In Iovance C-144-01 Study In Journal Of Clinical Oncology

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today announced that the Journal of Clinical Oncology has published a manuscript of clinical data for Cohort 2 in the C-144-01 study of lifileucel TIL therapy in metastatic melanoma. Online open access to the publication is available at https://ascopubs.org/doi/full/10.1200/JCO.21.00612.